Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01096407 · ClinicalTrials.gov registry record
Role of Biomarkers in Muscle Pain and Joint Pain in Patients With Solid Tumors Receiving Paclitaxel
A clinical trial, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- 5
- Enrollment target
NCT01096407: Clinical Trial study, sponsored by Vanderbilt-Ingram Cancer Center.
NCT01096407 is a clinical trial that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01096407 was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- 5 participants
- Enrollment target
Study Summary
RATIONALE: Learning about pain in patients with cancer receiving paclitaxel may help plan treatment and may help patients live more comfortably. Studying samples of urine from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to muscle and joint pain. PURPOSE: This phase I trial is studying the role of biomarkers in muscle pain and joint pain in patients with solid tumors receiving paclitaxel.
Primary Outcome
Change in amount of PGE-M in the urine from before administration of paclitaxel to 4 days after treatment.
Interventions
- OTHER laboratory biomarker analysis
- OTHER questionnaire administration
- PROCEDURE assessment of therapy complications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2009-11 |
| Est. Completion | 2010-11 |
Why NCT01096407 stopped before completion
NCT01096407 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 5 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01096407 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01096407 about?
NCT01096407 is a clinical study titled "Role of Biomarkers in Muscle Pain and Joint Pain in Patients With Solid Tumors Receiving Paclitaxel". RATIONALE: Learning about pain in patients with cancer receiving paclitaxel may help plan treatment and may help patients live more comfortably. Studying samples of urine from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to muscle and joint...
What is the current status of trial NCT01096407?
This trial is currently terminated. The enrollment target is 5 participants. The study started on 2009-11. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01096407?
The interventions under investigation include: laboratory biomarker analysis (OTHER), questionnaire administration (OTHER), assessment of therapy complications (PROCEDURE).
Who is sponsoring clinical trial NCT01096407?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia